Debut is a vertically integrated synthetic biology company that is spearheading the creation of innovative and novel high-performing active ingredients in beauty.
Debut creates advanced continuous manufacturing approaches for the production of small and large molecules harnessing the power of biocatalysis.
Debut Biotechnology was founded in 2019 by Joshua Britton, Brady Beauchamp, and Gregory Weiss. The company is headquartered in San Diego, California.
Debut is the only player in the biotech space with full vertical integration capabilities incorporating ingredient discovery, finished clinically-backed scalable ingredients and brands on shelf, all delivered at unprecedented speed.
Debut's proprietary Bio2Consumer™ platform spans ingredient discovery, cell-free, biofermentation, formulation, clinical trials and brand creation. The platform utilizes cell-free and advanced fermentation approaches such as continuous biomanufacturing to overcome the limitations of traditional methods, dramatically reducing the need for space, water, and expensive and unsustainable inputs.
Debut's technology also improves traditional ingredient manufacturing. The platform comprises a proprietary database of over 3.8 million pre-clinical data points to find and discover new ingredients that address beauty consumer needs.
Debut is backed by Material Impact, KdT Ventures, Better Ventures, BOLD, L'Oréal, FTW Ventures, Cultivian Sandbox Ventures, Fine Structure Ventures, ACVC Ventures, GS Futures, Cavallo Ventures, and others. The company raised $40M in an additional Series B round on Oct 19, 2023. This is an extension of previous $34M raised in Jun 2023 to bring its Series B total to $74M. The additional investment brings Debut's overall funding to $100.2M to date.